Type 1 Diabetes

Adults with type 2 diabetes assigned an oral formulation of human insulin achieved a clinically meaningful reduction in HbA1c compared with those assigned placebo, according to a press release from Oramed Pharmaceuticals.

The factors associated with increased depressive symptoms among youths with diabetes vary based on diabetes type, according to findings published in Pediatric Diabetes.

Adults with type 1 diabetes who use cannabis products are more than twice as likely to develop diabetic ketoacidosis as those who do not use cannabis products, according to findings published in Diabetes Care.

The New England Journal of Medicine recently published a breakthrough study on the so-called artificial pancreas.

CHICAGO — Health care providers who treat patients with type 2 diabetes still need to include insulin among therapeutic options, and it may even be prudent to consider it earlier in the treatment process, according to a presenter at the Cardiometabolic Health Congress.

Among adults with type 1 diabetes, those who used real-time continuous glucose monitoring with any form of insulin delivery experienced significantly lower HbA1c and spent more time in range and less time in hypoglycemia at 3 years compared with those who used self-monitoring blood glucose, according to real-world data published in Diabetes Care.

Women with type 1 diabetes have more coronary artery calcium compared with women without diabetes, and this difference only widens during menopause, potentially increasing cardiovascular risk, according to findings published in Diabetes Care.

The FDA cleared a second interoperable insulin pump for use in an automated insulin delivery system, and a nonhormonal drug compound was associated with fewer hot flashes and lower symptom severity in menopausal women.

Aerami Therapeutics, formerly Dance Biopharm, announced this week it is rebranding and expanding its pipeline to include several inhaled endocrine therapies, according to a company press release.

Adults with type 1 diabetes assigned to a mealtime, liver-targeted insulin using hepatocyte-directed vesicle technology for 6 months experienced a similar reduction in HbA1c when compared with similar adults assigned to insulin lispro, according to findings published in Diabetes Care.